Metastatic Hormone Refractory Prostate Cancer Not Yet Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Not Yet Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03805594177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate CancerTreatment